Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2022 Jan 27

PMID 35083493

Authors

Danielle Rogner

Tilo Biedermann

Felix Lauffer

Affiliations

Soon will be listed here.

Citing Articles

Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis.

Freitas E, Paiva Lopes M, Cruz M, Sousa D, Valente A, Duarte B Clin Drug Investig. 2023; 44(1):87-90.

PMID: 38114780 DOI: 10.1007/s40261-023-01335-x.

Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.

Reguiai Z, Becherel P, Perrot J, Fougerousse A, Begon E, Poreaux C Acta Derm Venereol. 2023; 103:adv14153.

PMID: 37800349 PMC: 10566517. DOI: 10.2340/actadv.v103.14153.

Atopic Dermatitis: Disease Features, Therapeutic Options, and a Multidisciplinary Approach.

Lugovic-Mihic L, Mestrovic-Stefekov J, Potocnjak I, Cindric T, Ilic I, Lovric I Life (Basel). 2023; 13(6).

PMID: 37374201 PMC: 10305021. DOI: 10.3390/life13061419.

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.

Thyssen J, de Bruin-Weller M, Costanzo A, Grond S, Schuster C, Liu C Adv Ther. 2023; 40(8):3574-3587.

PMID: 37332021 PMC: 10329959. DOI: 10.1007/s12325-023-02528-8.

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.

Boesjes C, Kamphuis E, Zuithoff N, Bakker D, Loman L, Spekhorst L Acta Derm Venereol. 2022; 102:adv00820.

PMID: 36420885 PMC: 9811281. DOI: 10.2340/actadv.v102.3978.

References

Lauffer F, Ring J . Target-oriented therapy: Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2016; 21(1):81-9. DOI: 10.1517/14728214.2016.1146681. View

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32(6):850-878. DOI: 10.1111/jdv.14888. View

Oranje A . Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011; 41:149-155. DOI: 10.1159/000323308. View

Paller A, Bansal A, Simpson E, Boguniewicz M, Blauvelt A, Siegfried E . Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2019; 21(1):119-131. PMC: 6989562. DOI: 10.1007/s40257-019-00478-y. View

Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M . The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001; 10(1):11-8. DOI: 10.1034/j.1600-0625.2001.100102.x. View

Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R . Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020; 183(2):242-255. DOI: 10.1111/bjd.18898. View

Reich K, DeLozier A, Nunes F, Thyssen J, Eichenfield L, Wollenberg A . Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2020; 33(3):1521-1530. DOI: 10.1080/09546634.2020.1839008. View

Singh R, Finlay A . Dermatology Life Quality Index use in skin disease guidelines and registries worldwide. J Eur Acad Dermatol Venereol. 2020; 34(12):e822-e824. DOI: 10.1111/jdv.16701. View

Reich A, Heisig M, Phan N, Taneda K, Takamori K, Takeuchi S . Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2011; 92(5):497-501. DOI: 10.2340/00015555-1265. View

10.

Reich K, Kabashima K, Peris K, Silverberg J, Eichenfield L, Bieber T . Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020; 156(12):1333-1343. PMC: 7527941. DOI: 10.1001/jamadermatol.2020.3260. View

11.

Hajar T, Gontijo J, Hanifin J . New and developing therapies for atopic dermatitis. An Bras Dermatol. 2018; 93(1):104-107. PMC: 5871372. DOI: 10.1590/abd1806-4841.20187682. View

12.

Blauvelt A, Rosmarin D, Bieber T, Simpson E, Bagel J, Worm M . Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019; 181(1):196-197. PMC: 6850039. DOI: 10.1111/bjd.17703. View

13.

Cotter D, Schairer D, Eichenfield L . Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2017; 78(3 Suppl 1):S53-S62. DOI: 10.1016/j.jaad.2017.12.019. View

14.

Averitt A, Weng C, Ryan P, Perotte A . Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020; 3:67. PMC: 7214444. DOI: 10.1038/s41746-020-0277-8. View

15.

Ring J, Zink A, Arents B, Seitz I, Mensing U, Schielein M . Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019; 33(7):1331-1340. DOI: 10.1111/jdv.15634. View